Leerink Partnrs Estimates Zymeworks’ Q1 Earnings (NYSE:ZYME)

Zymeworks Inc. (NYSE:ZYME) – Analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Zymeworks in a research note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst A. Berens expects that the company will earn ($0.51) per share for the quarter. The consensus estimate for Zymeworks’ current full-year earnings is ($1.39) per share. Leerink Partnrs also issued estimates for Zymeworks’ Q2 2025 earnings at ($0.59) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($1.09) EPS, FY2026 earnings at ($1.30) EPS and FY2027 earnings at ($1.17) EPS.

Several other analysts also recently weighed in on the stock. Citigroup lifted their target price on shares of Zymeworks from $18.00 to $19.00 and gave the company a “buy” rating in a report on Friday, March 7th. Lifesci Capital started coverage on Zymeworks in a research report on Tuesday, March 11th. They set an “outperform” rating and a $30.00 price objective for the company. Wells Fargo & Company upped their target price on shares of Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a report on Thursday, December 19th. HC Wainwright lifted their price objective on Zymeworks from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Monday, March 10th. Finally, JPMorgan Chase & Co. raised shares of Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price target on the stock in a research note on Monday, December 16th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $21.00.

Zymeworks Stock Down 1.6 %

NYSE ZYME opened at $12.72 on Thursday. Zymeworks has a 52-week low of $7.97 and a 52-week high of $17.70. The business’s 50-day moving average price is $13.72 and its 200 day moving average price is $13.68. The firm has a market cap of $885.02 million, a P/E ratio of -8.48 and a beta of 1.13.

Institutional Trading of Zymeworks

Several large investors have recently added to or reduced their stakes in the business. Sterling Capital Management LLC increased its stake in Zymeworks by 781.5% during the 4th quarter. Sterling Capital Management LLC now owns 1,719 shares of the company’s stock valued at $25,000 after buying an additional 1,524 shares during the period. AlphaQuest LLC raised its holdings in Zymeworks by 480.2% during the 4th quarter. AlphaQuest LLC now owns 2,808 shares of the company’s stock worth $41,000 after buying an additional 2,324 shares during the period. FMR LLC lifted its position in shares of Zymeworks by 84.2% in the 3rd quarter. FMR LLC now owns 3,336 shares of the company’s stock valued at $42,000 after acquiring an additional 1,525 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Zymeworks in the fourth quarter worth $108,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Zymeworks by 343.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 9,704 shares of the company’s stock valued at $142,000 after purchasing an additional 7,518 shares during the period. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Paul Andrew Moore sold 21,200 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $14.92, for a total transaction of $316,304.00. Following the completion of the transaction, the insider now owns 14,741 shares of the company’s stock, valued at approximately $219,935.72. The trade was a 58.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Kenneth Galbraith sold 57,291 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $14.92, for a total transaction of $854,781.72. Following the transaction, the chief executive officer now directly owns 47,543 shares of the company’s stock, valued at $709,341.56. The trade was a 54.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have bought 1,507,168 shares of company stock worth $19,339,774 and have sold 89,601 shares worth $1,336,847. 1.92% of the stock is currently owned by company insiders.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.